CRISPR, crispr genome editing system - Part 5

Finding Enhancers with CRISPR

crispr image5
While several groups are working to apply the CRISPR/Cas9 system for clinical purposes, some are using the tool to address fundamental questions about biology. Reuven Agami, a professor of genetics at the Netherlands Cancer Institute in Amsterdam, and his colleagues recently applied CRISPR to search for regulatory enhancer elements throughout the genome. They targeted the Cas9 nuclease to previously identified enhancer elements—transcription factor-binding DNA sequences that distally regulate gene expression—of two transcription factors: p53, and estrogen receptor alpha (ERα), which are both frequently mutated and deregulated in cancer. The team’s findings, published today (January 11) in Nature Biotechnology,highlight key enhancer sequences of these two proteins, and demonstrate the utility of CRISPR for the systematic study of noncoding DNA sequences. Two...
Read More..

We routinely say ‘Crispr’ing’ when we talk about changing specific genes – Paul Knoepfler, a biologist at the University of California

A new gene-editing technology has been relentlessly hyped over the past year, and it goes by a catchy if rather incongruous acronym: Crispr. Hailed as the breakthrough of 2015 by Science Magazine, Crispr could potentially help eradicate diseases like malaria and, more controversially, could be used to modify the DNA of human embryos. But it’s safe to say that Crispr would not be grabbing the headlines if it were known by its full name: “clustered regularly-interspaced short palindromic repeats.” The acronym emerged out of email exchanges in 2001 between two microbiologists: Francisco Mojica of the University of Alicante in Spain, and Ruud Jansen, then at Utrecht University in the Netherlands. A team led by Dr. Jansen is believed to be...
Read More..

Top 10 CRISPR predictions for New Year 2016

CRISPR is the hottest new biotechnology and the top development of 2015 according to Science Magazine. What will the new year of 2016 bring on the CRISPR front? It’s clear there will be more meetings on CRISPR ethics and policy (heck, we are having one right here at UC Davis on May 26), but what else is coming? Below are my top 10 CRISPR predictions for the new year in no particular order. What are your CRISPR predictions? For more on my thinking on CRISPR and the future, also please take a look at my new book, GMO Sapiens and for the extreme case of what could go wrong see my TED talk. The CRISPR predictions. The Noah’s arc of CRISPR-y critters continues...
Read More..

Bayer, CRISPR Therapeutics Launch JV to Develop CRISPR/Cas9 Treatments

NEW YORK (GenomeWeb) – Switzerland’s CRISPR Therapeutics and Germany’s Bayer today announced a yet unnamed joint venture to develop ways to deliver CRISPR/Cas9 genome editing in a clinical setting. The deal brings together Bayer’s experience in protein engineering and knowledge of human diseases with CRISPR Therapeutics’ CRISPR/Cas9 intellectual property and genome editing expertise, the firms said in a statement. Under the terms of the agreement, the partners will launch the joint venture to find, develop, and commercialize new therapies for blood disorders, blindness, and congenital heart disease. Bayer will provide at least $300 million over five years for R&D expenses as well as acquire a minority stake in CRISPR Therapeutics or $35 million.  Any newly created intellectual property from the...
Read More..


2016 IS GOING TO BE A BIG YEAR FOR THE GENE EDITING TECHNIQUE The gene-editing technique called CRISPR has the much-hyped potential to revolutionize medicine, deliver designer babies, and end global hunger. Developed from a mechanism found in bacteria, CRISPR allows scientists to cut-and-paste DNA with unprecedented precision. The researchers behind its discovery are favorites to win Nobel prizes in 2016. In the three years since CRISPR was introduced, it has been adopted by thousands of scientists worldwide. Already, they’ve used the technique to create hypermuscular beagles and pigs that can grow human organs for transplant. Innovations that used to take many years to realize can now be made in mere months. “The technology is pretty darn fast,” said Dan...
Read More..

Genome-editing revolution: My whirlwind year with CRISPR

Jennifer Doudna, a pioneer of the revolutionary genome-editing technology, reflects on how 2015 became the most intense year of her career — and what she’s learnt. Illustration By David Parkins Expand Some 20 months ago, I started having trouble sleeping. It had been almost two years since my colleagues and I had published a paper1 describing how a bacterial system called CRISPR–Cas9 could be used to engineer genomes.I had been astounded at how quickly labs around the world had adopted the technology for applications across biology, from modifying plants to altering butterfly-wing patterns to fine-tuning rat models of human disease. At the same time, I’d avoided thinking too much about the philosophical and ethical ramifications of widely accessible tools for...
Read More..

‘We all kind of marvel at how fast this took off’

On a warm September afternoon on the verdant campus of Long Island’s Cold Spring Harbor Laboratory, an elite cadre of scientists gathered to discuss a simple yet incredibly powerful new genetic technology. Jennifer Doudna was dressed casually in a blazer and jeans, with a scarf tossed gently around her neck to compliment a loose bob of blonde hair. Raised in Hilo, Hawaii, she retains a hint of the friendly islander vibe, even though she’s been recently thrust into the scientific spotlight. A biochemist at the University of California, Berkeley, Doudna is widely credited as one of the pioneers of a genetic technology that lets scientists tweak the DNA of practically any living creature. Known as CRISPR/Cas9, the technique has been...
Read More..

Bayer and CRISPR Therapeutics AG join Forces to Discover, Develop and Commercialize Potential Cures for Serious Genetic Diseases

crispr image14
Leverkusen, Germany and Basel, Switzerland, December 21, 2015 – Bayer and CRISPR Therapeutics have entered into an agreement to create a joint venture (JV) to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients. The JV is the first investment by the newly established Bayer LifeScience Center (BLSC), which operates as...
Read More..

Mammoth may be resurrected sooner than you think

crispr mammoth
Of all the varied and incredible possibilities presented by the controversial new gene-editing technique known as CRISPR-Cas9, perhaps the most intriguing are efforts to bring animals back from extinction. Candidates for de-extinction, as the process is known, include species like the passenger pigeon (the last one died in captivity in 1914), the dodo (last seen in 1662) and the sea cow (1768, a mere 27 years after it had been discovered by Europeans.) These projects are not pipe dreams. Dr. George Church, a molecular biologist at Harvard University who is working on such projects, estimates that a variation of the first new woolly mammoth (which disappeared some 4,000 years ago) may be born as soon as seven years from now. Like...
Read More..